MXPA01006511A - Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes. - Google Patents

Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes.

Info

Publication number
MXPA01006511A
MXPA01006511A MXPA01006511A MXPA01006511A MXPA01006511A MX PA01006511 A MXPA01006511 A MX PA01006511A MX PA01006511 A MXPA01006511 A MX PA01006511A MX PA01006511 A MXPA01006511 A MX PA01006511A MX PA01006511 A MXPA01006511 A MX PA01006511A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
combination
insulin
insulin sensitizers
Prior art date
Application number
MXPA01006511A
Other languages
English (en)
Inventor
Mark D Erion
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of MXPA01006511A publication Critical patent/MXPA01006511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se proporcionan composiciones farmaceuticas que contienen un inhibidor de FBPasa y un sensibilizador de insulina asi como tambien metodos para el tratamiento de diabetes y enfermedades que responden al control glicemico incrementado, un mejoramiento en la sensibilidad a la insulina, una reduccion en los niveles de insulina, o un aumento de la secrecion de insulina.
MXPA01006511A 1998-12-24 1999-12-22 Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes. MXPA01006511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
PCT/US1999/030713 WO2000038666A2 (en) 1998-12-24 1999-12-22 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES

Publications (1)

Publication Number Publication Date
MXPA01006511A true MXPA01006511A (es) 2004-03-19

Family

ID=22357016

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01006511A MXPA01006511A (es) 1998-12-24 1999-12-22 Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes.

Country Status (25)

Country Link
EP (1) EP1143955B1 (es)
JP (1) JP2003515523A (es)
KR (3) KR20060114724A (es)
CN (3) CN1714866A (es)
AT (1) ATE300288T1 (es)
AU (1) AU771039B2 (es)
BR (1) BR9917005A (es)
CA (1) CA2354053A1 (es)
CZ (1) CZ20012353A3 (es)
DE (1) DE69926400T2 (es)
DK (1) DK1143955T3 (es)
ES (1) ES2246586T3 (es)
HK (1) HK1046863B (es)
HU (1) HUP0402506A3 (es)
ID (1) ID30237A (es)
IL (2) IL143569A0 (es)
MX (1) MXPA01006511A (es)
NO (1) NO20013115L (es)
NZ (1) NZ512219A (es)
PL (1) PL352756A1 (es)
PT (1) PT1143955E (es)
RU (2) RU2227749C2 (es)
SK (1) SK9172001A3 (es)
WO (1) WO2000038666A2 (es)
ZA (1) ZA200105016B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2343027A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
US6965033B2 (en) 1999-12-22 2005-11-15 Metabasis Therapeutics, Inc. Bisamidate phosphonate prodrugs
RU2002126616A (ru) 2000-03-08 2004-03-20 Метабэйсис Терапьютикс, Инк. (Us) Новые арильные ингибиторы фруктозо-1, 6-бисфосфатазы
CZ20035A3 (cs) * 2000-07-06 2003-05-14 Metabasis Therapeutics, Inc. Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
CA2485702C (en) 2002-05-13 2011-07-19 Metabasis Therapeutics, Inc. Novel phosphonic acid based prodrugs of pmea and its analogues
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
JP4719465B2 (ja) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー．ブイ． インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
SI1611112T1 (sl) * 2003-02-11 2012-12-31 Vernalis (R&D) Limited Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
EA013249B1 (ru) * 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
WO2006023515A2 (en) * 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
US20070259928A1 (en) * 2004-12-13 2007-11-08 Taishi Yoshida Medicinal Composition for Treating Diabetes
CN101115483A (zh) * 2004-12-15 2008-01-30 第一三共株式会社 含有FBPase抑制剂的药物组合物
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9631825B2 (en) 2012-12-18 2017-04-25 Nortek Air Solutions, Llc Air filter assembly
CN106061984A (zh) 2014-02-13 2016-10-26 配体药物公司 前药化合物及其用途
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
IL93164A0 (en) * 1989-01-24 1990-11-05 Gensia Pharma Purine nucleosides and their medical use
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt) * 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase

Also Published As

Publication number Publication date
EP1143955B1 (en) 2005-07-27
DE69926400T2 (de) 2006-05-24
RU2227749C2 (ru) 2004-04-27
ES2246586T3 (es) 2006-02-16
SK9172001A3 (en) 2002-04-04
CN100352505C (zh) 2007-12-05
CZ20012353A3 (cs) 2001-12-12
CN101164618A (zh) 2008-04-23
ZA200105016B (en) 2002-09-19
WO2000038666A3 (en) 2001-11-29
EP1143955A3 (en) 2002-08-28
RU2003132054A (ru) 2005-04-20
HK1046863B (zh) 2008-07-25
NZ512219A (en) 2004-12-24
AU771039B2 (en) 2004-03-11
HUP0402506A3 (en) 2007-05-29
KR100689943B1 (ko) 2007-03-08
ATE300288T1 (de) 2005-08-15
IL143569A0 (en) 2002-04-21
KR20070046210A (ko) 2007-05-02
KR20060114724A (ko) 2006-11-07
NO20013115D0 (no) 2001-06-21
AU2058300A (en) 2000-07-31
PL352756A1 (en) 2003-09-08
HK1046863A1 (en) 2003-01-30
ID30237A (id) 2001-11-15
NO20013115L (no) 2001-08-24
EP1143955A2 (en) 2001-10-17
DE69926400D1 (de) 2005-09-01
HUP0402506A2 (hu) 2005-04-28
KR20010099942A (ko) 2001-11-09
PT1143955E (pt) 2005-11-30
IL143569A (en) 2006-06-11
CN1714866A (zh) 2006-01-04
CN1350466A (zh) 2002-05-22
BR9917005A (pt) 2002-04-02
CA2354053A1 (en) 2000-07-06
DK1143955T3 (da) 2005-11-14
WO2000038666A2 (en) 2000-07-06
JP2003515523A (ja) 2003-05-07

Similar Documents

Publication Publication Date Title
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
MY151032A (en) Treatment of tnf? related disorders
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
UA85041C2 (ru) Способ лечения кишечной непроходимости
AU7371600A (en) Use of alpha-linolenic acid metabolites for treatment or prevention of cancer
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
AU7564396A (en) Rac-proteine kinase as therapeutic agent or in diagnostics
BG105264A (en) New use of taxoid derivatives
IL186356A0 (en) Method of treating of preventing type-2 diabetes
WO2003035048A3 (en) Methods for the treatment of osteoarthritis and compositions thereof
WO2003103597A3 (en) DIAGNOSIS AND TREATMENT OF DIABETES AND INSULIN RESISTANCE
WO2003103601A3 (en) DIAGNOSIS AND TREATMENT METHODS FOR DIABETES AND INSULIN RESISTANCE
AU5434899A (en) Cancer treatment
AU5890499A (en) Use of composition in the treatment of schizophrenia
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
UA30659A (uk) Спосіб купіровання опіатної залежності
UA32255A (uk) Спосіб лікування цукрового діабету

Legal Events

Date Code Title Description
FG Grant or registration